uniQure (NASDAQ:QURE) Is Now Covered By Wells Fargo. What can We Expect?

May 16, 2018 - By Migdalia James

uniQure N.V. (NASDAQ:QURE) Logo

Why Has Wells Fargo Given uniQure (NASDAQ:QURE) a $47 Price Target

Wells Fargo has just issued a Outperform rating for uniQure (NASDAQ:QURE) shares. The firm initiated coverage on shares of QURE in analysts note shared with investors and clients on 16 May. This TP means upside of 46.10 % from the current stock price of uniQure (NASDAQ:QURE).

uniQure N.V. (NASDAQ:QURE) Ratings Coverage

Among 3 analysts covering uniQure NV (NASDAQ:QURE), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. uniQure NV has $6300 highest and $25.0 lowest target. $42.67’s average target is 32.64% above currents $32.17 stock price. uniQure NV had 5 analyst reports since December 1, 2017 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, March 20 by Janney Capital. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, March 15 report. The firm earned “Buy” rating on Wednesday, January 3 by Janney Capital. The rating was maintained by Leerink Swann with “Buy” on Monday, May 7.

The stock increased 2.09% or $0.66 during the last trading session, reaching $32.17. About 220,224 shares traded. uniQure N.V. (NASDAQ:QURE) has risen 293.97% since May 16, 2017 and is uptrending. It has outperformed by 282.42% the S&P500.

Analysts await uniQure N.V. (NASDAQ:QURE) to report earnings on August, 14. They expect $-0.68 earnings per share, up 18.07 % or $0.15 from last year’s $-0.83 per share. After $-0.59 actual earnings per share reported by uniQure N.V. for the previous quarter, Wall Street now forecasts 15.25 % negative EPS growth.

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company has market cap of $1.19 billion. The companyÂ’s principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It currently has negative earnings. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency.

More notable recent uniQure N.V. (NASDAQ:QURE) news were published by: Globenewswire.com which released: “uniQure Announces Proposed Public Offering” on May 01, 2018, also Benzinga.com with their article: “Chardan’s Top Pick For 2018: Gene Therapy Firm Uniqure” published on April 24, 2018, Seekingalpha.com published: “Premarket analyst action – healthcare” on May 16, 2018. More interesting news about uniQure N.V. (NASDAQ:QURE) were released by: Globenewswire.com and their article: “uniQure Announces to Present at Multiple Conferences in May” published on April 27, 2018 as well as Seekingalpha.com‘s news article titled: “Key events next week – healthcare” with publication date: May 11, 2018.

uniQure N.V. (NASDAQ:QURE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.